Abstract:Bacillus licheniformis produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4-20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8-42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by B. licheniformis as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of B. licheniformis to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria.

Biopharmaceutical potential of lichens

Recent advances in research for potential utilization of unexplored lichen metabolites

Endolichenic Fungi: A Promising Medicinal Microbial Resource to Discover Bioactive Natural Molecules—An Update

Nutritional and Health-Promoting Effects of Lichens Used in Food Applications

Discovery and excavation of lichen bioactive natural products

Lichen and its Microbiome as an Untapped Source of Anti‐biofilm Compounds

Linking Lichen Metabolites to Genes: Emerging Concepts and Lessons from Molecular Biology and Metagenomics

Towards the Use of Lichens as a Source of Bioactive Substances for Topical Applications

Enhanced accumulation of biologically active compounds in lichens with potential functional food applications

Phytochemical Characterization and Pharmacological Properties of Lichen Extracts from Cetrarioid Clade by Multivariate Analysis and Molecular Docking

A Review of Laboratory Requirements to Culture Lichen Mycobiont Species

Antimicrobial Activities of Medicinally Important Lichen Extracts Against Human Pathogenic Bacteria and Fungi

Comparative analysis of antimicrobial, antioxidant activities and phytochemicals of Himalayan lichens

A New Rare Halogenated Depside From Lichen And Study Of Its Anti‐Proliferative Activity

Mushrooms as Potential Sources of Active Metabolites and Medicines

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Chemical Constituents Isolated from the Lichen Biome of Selected Species Native to North America

Investigation of Antimicrobial and Antioxidant Activity of Lichen and its Chemical Isolates, α-Alectoronic Acid and α-Collatolic Acid

Advances in Research on Bioactivity, Toxicity, Metabolism, and Pharmacokinetics of Usnic Acid In Vitro and In Vivo

In vitro and in vivo assessment of antimicrobial, enzymatic, and antifouling properties of self‐potent lichen symbiotic bacteria

Unearthing nature's remedy: An exploration into Lycopodium's medicinal and therapeutic potential